Document is current
Any future updates will be listed below
-
Authors
Bug, Gesine https://orcid.org/0000-0003-2359-131X
Labopin, Myriam
Byrne, Jennifer L. https://orcid.org/0000-0002-9381-1851
Mielke, Stephan
Orchard, Kim https://orcid.org/0000-0003-2276-3925
Paneesha, Shankara https://orcid.org/0000-0002-7446-011X
Potter, Victoria
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Besley, Caroline
Snowden, John A. https://orcid.org/0000-0001-6819-3476
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Clark, Andrew
Crawley, Charles
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Brissot, Eolia https://orcid.org/0000-0003-4471-418X
Giebel, Sebastian https://orcid.org/0000-0002-4827-4401
Ciceri, Fabio https://orcid.org/0000-0003-0873-0123
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
- License Information
-
More Information
Article History
Received: 3 October 2025
Revised: 15 December 2025
Accepted: 9 February 2026
First Online: 6 March 2026
Competing interests
: GB received honoraria from BMS, Gilead, Jazz, Medac, Novartis and Sanofi and travel support from Gilead, Jazz and Sanofi. SM received research and travel support from Gilead/KITE; Member of Speakers Bureau of BMS, Novartis, Janssen and Pfizer; DSMB membership for Immunicum/Mendes and Miltenyi; Founder/leadership of SWECARNET. The other authors declare no conflict of interest.
: This study was approved by the ALWP of the EBMT institutional review board and conducted per the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave informed consent authorizing the use of their personal information for research purposes.
